Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020

Article Gastroenterology & Hepatology

Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines

Anju Murayama et al.

Summary: This study found extensive financial conflicts of interest between pharmaceutical companies and guideline authors in Japan, with over 40% of recommendations based on low-quality evidence. The Japanese Society of Gastroenterology guideline development process lacks transparency and sufficient conflict of interest policies compared to global standards.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Rheumatology

Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States

Hanano Mamada et al.

Summary: This study aimed to assess financial conflicts of interest (COI) and nonfinancial COI among psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan and the US, and to evaluate the quality of evidence and strength of recommendations of PsA CPGs. The study found that approximately 91.3% of Japanese authors and 84.0% of US authors received at least one payment between 2016 and 2018. The average payment amount per author was $145,018 in Japan and $162,825 in the US. Furthermore, undisclosed financial COI were found in 78.3% of authors of the JDA PsA CPG and 48.0% of authors of the ACR PsA CPG.

ARTHRITIS CARE & RESEARCH (2023)

Add to Collection

Article Medicine, General & Internal

Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study

Marie Clinckemaillie et al.

Summary: This study aims to investigate the financial relationships between key opinion leader (KOL) or non-KOL physicians and pharmaceutical and device companies in France. The results show that KOLs have extensive financial ties with the industry, receiving high-value gifts, remunerations, and contractual agreements.

BMJ OPEN (2022)

Add to Collection

Article Urology & Nephrology

Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline

Anju Murayama et al.

Summary: This study examined the financial and nonfinancial conflicts of interest among authors of CKD guidelines in Japan and found that most of the recommendations were based on low-quality evidence tied to pharmaceutical companies. The study also revealed the lack of rigorous and transparent conflict of interest policies for nephrology guideline authors.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Otorhinolaryngology

Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis

Anju Murayama et al.

Summary: The study revealed significant financial relationships between allergic rhinitis CPG authors and pharmaceutical companies in Japan, particularly those marketing novel drugs. Additionally, authors had relatively high self-citation rates, indicating the need for more rigorous COI management strategies.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society

Anju Murayama et al.

DISEASES OF THE ESOPHAGUS (2022)

Add to Collection

Review Medicine, General & Internal

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review

Aaron P. Mitchell et al.

Summary: The study found that financial payments from the drug industry to U.S. physicians are associated with physician prescribing practices, including increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal